The Polaris Pharmaceutical’s new drug for mesothelioma has increased the three-year survival rate by fourfold, as published in the internationally renowned medical journal JAMA Oncology.
The breakthrough clinical trial of a rare and aggressive cancer treatment reveals: Polaris metabolic therapy drug, ADI-PEG 20, presents an innovative treatment approach that significantly enhances the survival rates of patients with malignant pleural mesothelioma (MPM), particularly demonstrating a fourfold increase in three-year survival rates compared to the placebo group.